Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy vs Concurrent Chemoradiotherapy in NSCLC
NCT00003803Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 1999
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Feb 1999; status: terminated.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003803.